Genmab

Genmab is a publicly traded international biotechnology company specializing in the creation and development of differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and preclinical product pipeline, and three proprietary next-generation antibody technologies.